Your session is about to expire
← Back to Search
AL3818 + Nivolumab for Cancer
Study Summary
This trial is testing a new cancer treatment combining two drugs, to see if it is safe and effective.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have any autoimmune or lung diseases.I am able to care for myself and perform daily activities.My cancer has spread to the lining of my brain and spinal cord.My condition worsened or came back within the last 6 months.I have hepatitis C and haven't completed treatment, with a detectable viral load.I have had a blood clot in my veins that was not treated in the last 6 months.I have no conditions that affect my ability to take or absorb medications.I haven't taken steroids or immunosuppressants in the last 14 days.I have HIV with a CD4+ count below 350 cells/uL.I have an infection that is not responding to treatment.I have had an organ transplant.I do not have active stomach ulcers or serious gut conditions, and I haven't had a gut perforation or abscess in the last month.It has been over 3 weeks since my last cancer treatment.I haven't had major heart or stroke issues in the last 6 months.I have severe heart failure.I have a wound, fracture, or ulcer that hasn't healed, or I have symptoms of peripheral vascular disease.I haven't had significant bleeding or blood clotting issues in the last 6 months.I have chronic hepatitis B or C with a detectable viral load.I haven't had major surgery in the last 28 days or minor surgery in the last 7 days.You have a known allergy or severe reaction to protein-based treatments or any major drug allergy in the past.Your heart's electrical activity (measured by an ECG) shows a longer than normal QT interval.I have another type of cancer that could affect this study's treatment.You have a disease that can be measured using a specific set of guidelines.I have AIDS and had an opportunistic infection in the last year.I have untreated brain metastases.I have STS, SCLC, or NSCLC and need treatment after my first one.My cancer has returned or spread and needs treatment, or there's no standard treatment for it.
- Group 1: AL3818 plus nivolumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there other examples of research using AL3818?
"There are 830 ongoing clinical trials that involve AL3818. Of these, 89 are Phase 3 studies. The vast majority of research is being conducted in Zürich, BE; however, there are 40560 locations running similar studies."
What is the maximum sample size for this experiment?
"That is correct. The online information from clinicaltrials.gov affirms that this trial, which was first announced on October 17th 2019, is presently recruiting patients. They are looking for 56 individuals total, who will be drawn from 1 site."
What conditions does AL3818 typically alleviate?
"AL3818 is a medication that oncologists often prescribe to treat malignant neoplasms. However, it can also palliate symptoms for patients suffering from unresectable melanoma, squamous cell carcinoma, and metastatic esophageal adenocarcinoma."
Are new participants being taken in for this research?
"That is accurate. The information available on clinicaltrials.gov affirms that this trial, which was initially posted on October 17th 2019, is looking for 56 patients from a single site."
Is this a fresh approach to testing?
"AL3818 has been under clinical investigation for a decade. In 2010, the first study was conducted by Medarex and involved 127 patients. The success of this initial Phase 1 trial led to the drug's approval. Currently, 830 different trials are ongoing in 2372 cities across 50 nations."
Share this study with friends
Copy Link
Messenger